Clinical Trial Update: Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia [Phase 2]

View source ↗

Summary

This update reports results from a Phase 2 efficacy and safety study evaluating cognitive deficits in adults with schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Cognitive Deficits in Schizophrenia | Phase 2 | Status: COMPLETED